Categories: HealthcareNews

LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results

LONDON–(BUSINESS WIRE)–#advancedcirculatorysupport–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2023 results prior to the call.


A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 206069. A replay will be available on the LivaNova website for 90 days following the call.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the next Company conference call. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382

Briana Gotlin
Director, Investor Relations

InvestorRelations@livanova.com

Deanna Wilke
VP, Corporate Communications

Corporate.Communications@livanova.com

Staff

Recent Posts

Defence Completes 2nd Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…

14 hours ago

Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…

15 hours ago

Axonics Stockholders Approve Merger Agreement with Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt…

15 hours ago

Pramana Achieves Industry-Leading Milestone with Digital Pathology 2.0 Technology

Over 6.5 Million Glass Slides Digitized in the Last 12 Months and 15 Billion Images…

15 hours ago

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or…

15 hours ago